Rashid K. Sayyid, MD, MSc

home / authors / rashid-k-sayyid-md-msc

Articles

Rashid K. Sayyid, MD, MSc, an expert on prostate cancer

The Role of Combination Therapy in mCRPC

Rashid K. Sayyid, MD, MSc
October 26th 2023

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.

Rashid K. Sayyid, MD, MSc, an expert on prostate cancer

Treatment Options for Nonmetastatic CRPC

Rashid K. Sayyid, MD, MSc
October 19th 2023

Rashid K. Sayyid, MD, MSc, gives a brief overview of treatment options for nonmetastatic castrate-resistant prostate cancer.

Rashid K. Sayyid, MD, MSc, an expert on prostate cancer

Treatment Approach for Patients With Metastatic CRPC

Rashid K. Sayyid, MD, MSc
October 19th 2023

Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer.

Rashid K. Sayyid, MD, MSc, an expert on prostate cancer

Overview of Castrate-Resistant Prostate Cancer (CRPC)

Rashid K. Sayyid, MD, MSc
October 19th 2023

An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer.

Rashid K. Sayyid, MD, MSc, an expert on prostate cancer

Systemic Therapy for Prostate Cancer

Rashid K. Sayyid, MD, MSc
October 5th 2023

A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.

Rashid K. Sayyid, MD, MSc, an expert on prostate cancer

Prostate Cancer Prognosis and Risk Stratification

Rashid K. Sayyid, MD, MSc
September 21st 2023

Rashid K. Sayyid, MD, MSc, describes the staging and risk stratification process for patients with prostate cancer and their effect on prognosis.

Latest Updated Articles

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
Published: April 24th 2025 | Updated: April 28th 2025
FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma
People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate: © stock.adobe.com.
Published: April 22nd 2025 | Updated: April 28th 2025
Support Patient Access and Education with the End Brain Cancer Initiative for GiveBIG 2025
The End Brain Cancer Initiative is currently seeking Primary Central Nervous System Lymphoma patients and care partners to participate in an online roundtable discussion: © stock.adobe.com.
Published: March 3rd 2025 | Updated: April 28th 2025
Primary Central Nervous System Lymphoma Patient and Care Partner Roundtable Hosted by the End Brain Cancer Initiative
Registration is now open for the 2025 Know All Your Treatment Options (KAYTO25) online patient disease education event/webinar: © stock.adobe.com.
Published: March 17th 2025 | Updated: April 28th 2025
Registration Open for the 2025 Know All Your Treatment Options Webinar Hosted by the End Brain Cancer Initiative
Each May, for over a decade, the End Brain Cancer Initiative (EBCI) has presented the National HOPE Award to a brain cancer patient who deeply inspires us: © stock.adobe.com.
Published: March 18th 2025 | Updated: April 28th 2025
Nominations Open for the End Brain Cancer Initiative’s 2025 National Patient Disease Education Initiative and HOPE Award
Illustration of bladder.
Published: April 22nd 2025 | Updated: April 28th 2025
Imfinzi Combination Shows Efficacy in Bladder Cancer Treatment